Low-dose treatment with Il2 across studies shows benefits in chronic graft-versus host

(Dana-Farber Cancer Institute) Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.